A Prospective Cohort Study Evaluating Risk of Local Recurrence Following Breast Conserving Surgery and Endocrine Therapy in Low Risk Luminal A Breast Cancer
This is a multicentre, single-arm prospective cohort study evaluating risk of ipsilateral
breast tumour recurrence(IBTR) following breast conserving surgery (BCS) in a group of women
postulated to be at low risk for recurrence. Women with luminal A breast cancer determined
by immunohistochemical(IHC) and other low risk clinical testing (see below) will be treated
with endocrine therapy (tamoxifen or aromatase inhibitor) for five years and will not be
treated with breast irradiation (BI). Subjects will be followed for 10 years and will be
assessed for recurrent disease, new primary cancer and survival.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society